As of close of business last night, Avidity Biosciences Inc’s stock clocked out at $20.02, up 4.60% from its previous closing price of $19.14. In other words, the price has increased by $+0.88 from its previous closing price. On the day, 1451754 shares were traded. RNA stock price reached its highest trading level at $20.60 during the session, while it also had its lowest trading level at $19.18.
Ratios:
To gain a deeper understanding of RNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On March 31, 2023, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $20.
On July 20, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $29.Chardan Capital Markets initiated its Buy rating on July 20, 2022, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 01 ’24 when Boyce Sarah sold 84,000 shares for $20.13 per share. The transaction valued at 1,691,306 led to the insider holds 112,117 shares of the business.
Boyce Sarah sold 5,092 shares of RNA for $51,582 on Jan 22 ’24. The President and CEO now owns 44,008 shares after completing the transaction at $10.13 per share. On Jan 22 ’24, another insider, Flanagan W. Michael, who serves as the CSTO of the company, sold 4,129 shares for $10.13 each. As a result, the insider received 41,827 and left with 35,871 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 1.53B and an Enterprise Value of 939.93M. For the stock, the TTM Price-to-Sale (P/S) ratio is 166.95 while its Price-to-Book (P/B) ratio in mrq is 3.17. Its current Enterprise Value per Revenue stands at 98.32 whereas that against EBITDA is -4.03.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $24.66, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 12.32, while the 200-Day Moving Average is calculated to be 9.34.
Shares Statistics:
It appears that RNA traded 1.17M shares on average per day over the past three months and 1.63M shares per day over the past ten days. A total of 79.28M shares are outstanding, with a floating share count of 70.81M. Insiders hold about 11.18% of the company’s shares, while institutions hold 94.80% stake in the company. Shares short for RNA as of Feb 15, 2024 were 7.73M with a Short Ratio of 6.60, compared to 7.34M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.74% and a Short% of Float of 9.85%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.95, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.67 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.71 and -$4.19 for the fiscal current year, implying an average EPS of -$3.2. EPS for the following year is -$3.58, with 6 analysts recommending between -$2.61 and -$4.65.
